Product image of Linezolid Hikma (Linezolid) supplied by GNH India

Linezolid Hikma

Active Ingredient:
Linezolid
Origin:
EU

Linezolid Hikma (Linezolid)

Linezolid, the active ingredient in Linezolid Hikma, is an oxazolidinone presented as an injectable solution for intravenous use. It treats infections caused by resistant Gram‑positive bacteria such as MRSA and VRE in hospitalized patients.

GNH India supplies Linezolid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hikma Farmacêutica (Portugal), S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linezolid is indicated for serious Gram‑positive bacterial infections and is used in hospital settings for the following conditions:

  • Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective against resistant strains, helping to clear the infection.
  • Vancomycin‑resistant Enterococcus (VRE) infections: provides an alternative treatment option for difficult‑to‑treat enterococcal disease.
  • Community‑acquired bacterial pneumonia: targets the causative Gram‑positive organisms and improves clinical outcomes.
  • Skin and soft tissue infections: reduces bacterial load in complicated cellulitis and wound infections.
  • Complicated intra‑abdominal infections: assists in controlling polymicrobial infections that include resistant Gram‑positive pathogens.

How It Works

  • Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the formation of the initiation complex required for translation. This action halts bacterial growth, rendering the organism unable to proliferate and allowing the host immune system to clear the infection.

Side Effects

Linezolid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools that may be self‑limiting.
  • Headache: transient cranial discomfort.
  • Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

  • Myelosuppression (e.g., thrombocytopenia, anemia, leukopenia): requires regular blood count monitoring.
  • Peripheral neuropathy: sensory changes that may be irreversible if untreated.
  • Serotonin syndrome when combined with serotonergic agents: can present with agitation, hyperreflexia, and fever.
  • Lactic acidosis: rare metabolic disturbance needing immediate medical attention.

Precautions & Warnings

When prescribing linezolid, clinicians should consider several safety measures:

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic dysfunction: assess liver enzymes regularly during treatment.
  • Concomitant serotonergic agents: avoid due to risk of serotonin syndrome.
  • Myelosuppression: perform complete blood count monitoring throughout therapy.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Linezolid interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

  • Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: risk of serotonin syndrome.
  • Monoamine oxidase inhibitors (MAOIs): may cause severe hypertension.
  • Rifampicin: induces metabolism and reduces linezolid exposure.

Moderate Interactions (Monitor Closely)

  • Warfarin: linezolid may increase INR, requiring closer coagulation monitoring.
  • Theophylline: plasma concentrations can rise, necessitating dose adjustment.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk when combined.

Frequently Asked Questions

Linezolid Hikma is employed for serious Gram‑positive bacterial infections, including methicillin‑resistant Staphylococcus aureus (MRSA), vancomycin‑resistant Enterococcus (VRE), community‑acquired bacterial pneumonia, complicated skin and soft‑tissue infections, and intra‑abdominal infections that involve resistant organisms.

Linezolid blocks bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the formation of the initiation complex required for translation. This halts bacterial growth, allowing the immune system to eliminate the pathogen.

The exact dose and duration of linezolid therapy are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. No fixed regimen is provided here.

Linezolid is classified as pregnancy category unknown; limited data exist. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus. Breastfeeding decisions should be made after consulting a healthcare professional.

To request Linezolid Hikma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Linezolid offers oral and intravenous options and is active against many resistant Gram‑positive organisms, whereas vancomycin requires intravenous administration and may be less effective against certain VRE strains. Linezolid’s unique mechanism reduces cross‑resistance but carries a distinct safety profile that must be monitored.

Linezolid Hikma should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves drug stability and potency.

Linezolid Hikma is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional under aseptic conditions, typically over a period defined by the prescriber.

Serious risks include myelosuppression (especially thrombocytopenia), peripheral neuropathy, serotonin syndrome when combined with serotonergic agents, and rare metabolic disturbances such as lactic acidosis. Prompt monitoring of blood counts and neurological status is essential.

Linezolid is contraindicated in patients with known hypersensitivity to linezolid or other oxazolidinones. Caution is advised for individuals taking serotonergic medications, those with pre‑existing severe myelosuppression, and patients with uncontrolled hypertension when combined with MAO inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linezolid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT